Jul 04, 2025
HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
Jun 26, 2025
HotSpot Therapeutics to Present Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
Jun 25, 2025
HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025
Jun 18, 2025
HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025
Nov 07, 2024
HotSpot Therapeutics Presents Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting
Oct 09, 2024
HotSpot Therapeutics to Present Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium
Oct 04, 2024
HotSpot Therapeutics to Present Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting
Sep 19, 2024
HotSpot Therapeutics Appoints Alison O'Neill, M.D., as Chief Medical Officer
Sep 12, 2024
HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024
Jul 17, 2024
HotSpot Therapeutics to Present Initial First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024
Jun 20, 2024
HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
May 20, 2024
HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma